Two Sigma Investments LP Increases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Two Sigma Investments LP grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 151.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 902,286 shares of the medical research company’s stock after purchasing an additional 543,545 shares during the quarter. Amgen makes up about 0.5% of Two Sigma Investments LP’s holdings, making the stock its 26th biggest position. Two Sigma Investments LP owned 0.17% of Amgen worth $235,172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of AMGN. Beck Mack & Oliver LLC raised its stake in Amgen by 0.7% during the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 34 shares in the last quarter. Blossom Wealth Management grew its holdings in shares of Amgen by 3.5% during the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock worth $284,000 after purchasing an additional 37 shares during the last quarter. Zullo Investment Group Inc. increased its position in shares of Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after purchasing an additional 37 shares in the last quarter. Trillium Asset Management LLC lifted its holdings in shares of Amgen by 4.2% in the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 37 shares during the last quarter. Finally, Evermay Wealth Management LLC boosted its position in shares of Amgen by 1.5% in the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company’s stock valued at $691,000 after purchasing an additional 38 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.76% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of several research analyst reports. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Erste Group Bank cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Bank of America increased their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 5th. Citigroup restated a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Piper Sandler reduced their target price on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a report on Friday. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $310.18.

Amgen Price Performance

Amgen stock opened at $272.41 on Monday. The company has a market cap of $146.48 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business has a fifty day moving average of $291.00 and a two-hundred day moving average of $287.86. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.96 earnings per share. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is currently 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.